Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild to moderate SARS-CoV-2 in Qatar

Ahmed Zaqout,Muna A. Almaslamani,Hiam Chemaitelly, Samar A. Hashim, Ajithkumar Ittaman, Abeir Alimam, Fatma Rustom,Joanne Daghfal,Mohammed Abukhattab,Sawsan AlMukdad,Anvar Hassan Kaleeckal,Ali Nizar Latif,Adeel A. Butt,Roberto Bertollini,Abdullatif Al-Khal,Ali S. Omrani,Laith J. Abu-Raddad

medRxiv (Cold Spring Harbor Laboratory)（2022）

引用 0|浏览0

暂无评分

摘要

AbstractEffectiveness of sotrovimab against severe, critical, or fatal COVID-19 was investigated in Qatar using a case-control study design at a time when BA.2 Omicron subvariant dominated incidence. Adjusted odds ratio of progression to severe, critical, or fatal COVID-19, comparing those sotrovimab-treated to those untreated, was 2.67-fold higher (95% CI: 0.60-11.91).

查看译文

关键词

antibody sotrovimab,high-risk,sars-cov

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要